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Abstract
In view of the fact that primary aldosteronism (PA) is a problem that is more prevalent than previously thought and its diagnosis is of 
greater clinical significance than previously believed, the Endocrine Society has recently published recommendations on the diagnosis and 
management of PA. Due to the fact that the currently available tests cannot be considered the gold standard in the diagnosis of PA and 
the discrepancies in the results of determination of aldosterone levels and plasma renin activity (PRA) are considerable the authors of this 
document do not provide strict cutoff values, leaving the interpretation of results to clinicians. This paper, which focuses on screening and 
confirmatory tests and on the aetiological diagnosis and treatment of PA, is based on the experience of the Department of Endocrinology, 
Diabetes and Internal Diseases, Medical University in Bialystok, Poland, but it also takes into account other points of view presented in 
papers published in the past few years. (Endokrynol Pol 2012; 63 (4): 324–336)
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Streszczenie
Biorąc pod uwagę fakt, że pierwotny aldosteronizm (PA) jest problemem występującym częściej niż wcześniej sądzono, a jego rozpoznanie 
ma istotniejsze znaczenie kliniczne niż dotąd uważano, Towarzystwo Endokrynologiczne opublikowało ostatnio rekomendacje dotyczące 
rozpoznawania i leczenia PA. Ze względu na to, że dostępnych obecnie testów nie można uważać za „złoty standard” w rozpoznawaniu PA, 
a rozbieżność uzyskiwanych wyników oznaczeń ALDO i PRA jest znaczna, autorzy tego dokumentu nie wskazali ścisłych poziomów odcię-
cia, pozostawiając interpretację wyników klinicystom. Dlatego niniejsze opracowanie, dotyczące badań przesiewowych i potwierdzających 
oraz diagnostyki etiologicznej i leczenia PA, oparto na doświadczeniu Kliniki Endokrynologii Uniwersytetu Medycznego w Białymstoku, 
ale uwzględniono także inne punkty widzenia, przedstawione w piśmiennictwie ostatnich lat. (Endokrynol Pol 2012; 63 (4): 324–336)
Słowa kluczowe: osoczowe stężenie aldosteronu, aktywność reninowa osocza, iloraz aldosteron–renina, testy potwierdzające
The history of discovering  
primary aldosteronism
Primary aldosteronism (PA) is commonly referred to in the 
medical literature as Conn’s syndrome, because Jerome 
Conn, who described this syndrome in a female patient 
with aldosterone-secreting adenoma in 1955, is consi- 
dered its discoverer [1]. However, two years earlier, Michał 
Lityński published, in Polish, a description of two cases 
of males who had died from renal failure in the course of 
malignant hypertension caused by adrenal cortex tumours 
[2]. In both cases the autopsy revealed adrenal tumours 
whose microscopic structure revealed large cells with 
foamy cytoplasm and small nuclei, typical of the glomeru-
lar layer of the adrenal cortex. Michał Lityński concluded 
his report with these words: “It must be assumed that in 
both cases the hypertension was caused by adrenocortical 
tumours, unilateral in one case and right-sided in the other 
case. The histology of the tumours revealed proliferation 
of cells resembling cells of the glomerular layer, i.e. the 
mineralocorticoid-producing layer. It allows us to believe 
that what we were dealing with was excessive production 
of these hormones”.
Michał Lityński’s report, almost unknown even in 
the Polish scientific literature, was brought to the at-
tention of the Polish medical community by Walenty 
Hartwig [3] in 1983 and by Franciszek Kokot in 1984 [4]. 
A proposal was also put forward to rename the syn-
drome “the Lityński-Conn syndrome” (Figure 1) [5]. 
Michał Lityński’s precedence in the discovery of PA 
was also recognised in “The Lancet” in 1991 [6] and in 
“Kaplan’s Clinical Hypertension” in 2002 [7].
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Introduction
Primary aldosteronism is characterised by an autono-
mous overproduction of aldosterone, a sodium-re-
taining hormone of the adrenal cortex. This process is 
caused by an adenoma composed of glomerular layer 
cells (aldosterone-producing adenoma, APA) or bilateral 
adrenal hyperplasia (BAH). Only exceptionally PA is 
caused by a carcinoma originating from glomerular 
layer cells. Retention of sodium and, secondarily, of 
water suppresses the secretion of renin by the juxtaglo-
merular apparatus in the kidneys, which in turn results 
in decreased serum levels of angiotensin II (AII) [7]. The 
main effects of aldosterone are reabsorption of sodium 
in the distal tubule of the nephron and secretion of 
potassium and hydrogen ions into the tubular lumen. 
Aldosterone excess leads to hypertension (HT) — as 
a result of increased volume of circulating blood and 
accumulation of sodium in smooth myocytes of the 
vascular walls (sodium is an important vasoconstriction 
factor) — and to hypokaliaemia and metabolic alkalosis 
[8]. Aldosterone receptor antagonists with or without 
other antihypertensive drugs are the treatment of choice 
in cases where BAH is identified as the cause of PA. If 
the diagnosis of aldosteronoma is established, unilateral 
adrenalectomy, most commonly laparoscopic, should 
be considered [9]. Surgery and drug treatment usually 
improves the quality of life by alleviating or, in some 
cases, eliminating HT and hypokaliaemia [10].
After Lityński’s discovery until not very long ago 
PA was considered a very rare cause of HT, account-
ing, roughly, for a mere 1% of the cases. This point of 
view was largely determined by a belief that further 
evaluation for aldosterone excess was only justified 
when hypokaliaemia was present. In the recent years, 
however, the opinions on the epidemiology of PA and 
its role in the pathogenesis of cardiovascular disease 
have changed significantly for two reasons.
Firstly, due to the widespread use of the ratio of 
plasma aldosterone concentration to plasma renin activ-
ity — ALDO/PRA ratio — proposed by Hiramatsu et al. 
in 1983 [11, 12] PA is currently diagnosed in as many as 
5–13% of hypertensive patients with most of them be-
ing normokalaemic [13, 14]. Based on the recent results 
the contribution of PA to the development of refractory 
HT is estimated at as much as 20% [15]. While some 
researchers have called this considerable “involvement” 
of PA in the aetiology of HT an epidemic, others, like 
Kaplan, question it, mainly due to the imperfection of 
aldosterone and PRA determinations [16].
Secondly, the reports published in the past few years 
suggest that aldosterone excess is a significant cardiovas-
cular risk factor that predisposes to inflammation, fibrosis 
and remodelling of the vascular wall independently of 
HT per se [17, 18]. PA significantly increases mortality due 
to myocardial infarction, stroke and arrhythmia [19, 20]. 
Increased albumin secretion, which is more severe than 
in patients with essential HT, is a marker of vascular dam-
age in the course of PA [18, 21]. It has been shown that 
restoration of normal aldosterone levels may suppress the 
process of adverse structural changes in vascular walls 
[22]. Therefore the diagnosis of PA not only offer an op-
portunity to provide effective treatment of HT but also 
a chance of reversing HT-independent adverse impact 
of aldosterone on the cardiovascular system.
In view of the fact that PA is a problem that is more 
prevalent than previously thought and its diagnosis 
is of greater clinical significance than previously be-
lieved, the Endocrine Society has recently published 
recommendations on the diagnosis and management 
of PA [23]. Due to the fact that the currently available 
tests cannot be considered the gold standard in the 
diagnosis of PA and the discrepancies in the results of 
determination of aldosterone levels and PRA are con-
siderable the authors of this document do not provide 
strict cutoff values, leaving the interpretation of results 
to clinicians. This paper, which focuses on screening 
and confirmatory tests and on the aetiological diagnosis 
and treatment of PA, is based on the experience of the 
Department of Endocrinology, Diabetes and Internal 
Diseases, Medical University in Bialystok, Poland, but 
it also takes into account other points of view presented 
in papers published in the past few years.
Figure 1. Michał Lityński (1906–1989) (reprinted from reference [5])
Rycina 1. Michał Lityński (1906–1989) (reprodukowano z [5])
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Screening tests
Who should be screened?
The Endocrine Society recommends that screening 
based on the calculation of the ALDO/PRA ratio (ARR, 
aldosterone-renin ratio) should be performed in patients 
from groups in which the incidence of PA is increased 
(Table I). These groups are patients with moderate to 
severe HT, which may or may not be refractory, patients 
with hypertension co-existent with hypokaliaemia 
(spontaneous or induced by diuretics) and/or adrenal 
incidentaloma, and patients with a family history of HT 
or a cardiovascular event before the age of 40 years. The 
Endocrine Society also recommends screening in all 
hypertensive first-degree relatives of patients with PA 
[23]. Some authors believe that all hypertensive patients 
should be screened, including those without hypoka-
laemia and without the family history, as the delayed 
diagnosis of PA leads to irreversible sequelae of HT and 
aldosterone excess and the delayed treatment of PA re-
duces the chances of achieving normal blood pressure 
values [24]. These authors note that screening before 
initiation of drug therapy makes it possible to avoid the 
effect of antihypertensive agents on serum aldosterone 
and PRA. Kaplan questions such a wide range of indica-
tions for screening for PA [25]. In particular, he points 
out that patients with moderate HT (defined as BP 
160–180/100–110 mm Hg) account for as many as 25% 
of hypertensive patients, while aldosteronoma accounts 
for about 1% of cases of adrenal incidentaloma [26, 27].
Screening for primary aldosteronism:  
the aldosterone–renin ratio
Although the determination of ARR is considered the 
most reliable method of screening for PA, its interpreta-
tion is complex, as it requires an individual assessment 
of the impact on numerous factors on the rennin–angio-
tensin–aldosterone system (RAAS). In order to reduce 
the percentage of false positive and false negative results 
first of all efforts should made to eliminate the influence 
of numerous interfering factors on the RAAS. Figure 2 
depicts the RAAS along with the physiological and 
pharmacological factors that affect this system. It also 
helps to elucidate the different effect of these factors 
on the individual elements of the system. The RAAS 
plays a key role in maintaining water and electrolyte 
homoeostasis and blood pressure, keeping the volume 
of circulating blood constant mainly be regulating the 
level of sodium, an ion that shows a high osmotic po-
tential. Potassaemia is the second to circulating blood 
volume significant factor co-dependent on the RAAS (it 
is both a regulated and a regulating factor). The level of 
hydration and kaliaemia are the most important factors 
that determine aldosterone secretion with the informa-
tion on the level of hydration is transmitted through 
the RAAS and high potassium levels directly stimulate 
aldosterone secretion. The third factor that stimulates 
aldosterone secretion, especially under conditions of 
suppressed renin activity (e.g. in PA), is adrenocortico-
Table I. Characteristics of groups of hypertensive patients 
(NT) in which primary aldosteronism (PA) is more prevalent
Tabela I. Charakterystyka grup chorych na nadciśnienie 
tętnicze (NT), u których częściej występuje pierwotny 
aldosteronizm (PA)
Moderate to severe hypertension
Refractory hypertension
Hypertension and hypokaliaemia (spontaneous or induced  
by diuretics)
Hypertension and adrenal incidentaloma
Hypertension and a family history of hypertension  
or a cardiovascular event before the age of 40 years
Hypertension and first-degree relatives with PA
Figure 2. The renin-angiotensin-aldosterone system along 
with the physiological and pharmacological factors affecting its 
homoeostasis; ALDO — aldosterone; R — renin; Na — sodium; 
K — potassium; S — sympathetic nervous system; PG — 
prostaglandins; NSAID — non-steroid anti-inflammatory drug; 
ACE — angiotensin converting-enzyme, ACEI — ACE inhibitors; 
AI/II — angiotensin I/II; AT2R
– — inhibition of the angiotensin 
receptor type 2; ACTH — adrenocorticotropic hormone; ≠/Ø — 
increase/decrease; +/– — stimulation/inhibition
Rycina 2. Układ renina–angiotensyna–aldosteron oraz czynniki 
fizjologiczne i farmakologiczne wpływające na jego równowagę; 
ALDO — aldosteron; R — renina; Na — sód; K — potas; 
S — układ współczulny (sympatyczny); PG — prostaglandyny, 
NSAID — niesteroidowe leki przeciwzapalne; ACE — konwertaza 
angiotensyny, ACEI — inhibitory ACE; AI/II — angiotensyna 
I/II; AT2R
– — inhibicja receptora angiotensyny typu 2; ACTH 
— kortykotropina; ≠/Ø — zwiększenie/zmniejszenie; +/– — 
pobudzenie/hamowanie
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tropic hormone (ACTH). Renin activity depends on the 
integration of three types of stimuli: a “flow-related” 
stimulus, an “electrolyte” stimulus and direct adrenergic 
stimulation. Reduced blood flow through the afferent 
arteriole of the juxtaglomerular apparatus results from 
systemic hypovolaemia, renal artery stenosis (the classic 
Goldblatt experiment) or intrarenal circulation abnor-
malities stimulate renin activity. Hyponatraemia and hy-
perkalaemia exert a similar effect, independently from 
each other. Stimulating factors transmitted through the 
sympathetic nervous system (stress and other states of 
hypercatecholaminaemia, e.g. phaeochromocytoma) 
are transmitted through stimulation of b2-adrenergic re-
ceptors and inhibition of a2-adrenergic receptors. Renin 
activity is also stimulated by locally secreted prostaglan-
dins, which is important in terms of the influence of the 
commonly used non-steroid anti-inflammatory drugs 
(NSAIDs) on the RAAS. Angiotensin II (AII) is an impor-
tant element of the RAAS. However, it is not the only 
mechanism whereby AII affects water and electrolyte 
balance and the regulation of blood pressure, as it is 
also an important vasoconstrictive factor, it increases 
antidiuretic hormone secretion and, independently 
from the RAAS, it increases sodium reabsorption [28].
The impact of posture, time of day and dietary 
sodium content on the sensitivity of ARR
The assumption of upright posture results in the 
activation of the RAAS and an increase in aldoster-
one levels (Figure 3). The increased renin activity 
results from a reduced renal blood flow caused by 
redistribution of blood flow to the lower limbs. In 
the group of patients with AII-responsive forms of 
PA, which includes all cases of BAH and some cases 
of APA, normal increases in PRA and ALDO are ob-
served upon the assumption of the upright position 
(a > 50% increase in ALDO compared to the level in 
the recumbent position). In most patients with APA, 
whose PA is AII-unresponsive, no significant effect of 
assuming the upright position on ALDO is observed 
[29, 30]. The head-up tilt test is not recommended 
for routine differentiation between BAH and APA 
due to its insufficient specificity. In a metaanalysis of 
16 published reports the specificity of the tilt test in 
246 patients with surgically confirmed APA was 85% 
[31]. In practice, in accordance with the recommen-
dations of the Endocrine Society, blood for screening 
determinations of PRA and ALDO is collected in the 
morning after 5–15 minutes’ rest in the sitting position 
and after 2 hours of keeping the chest in the upright 
position (the patient may stand, sit or walk during 
this time) [23]. The upright position ensures a higher 
sensitivity of the screening tests, as more than 2/3 of 
the cases of PA are AII-responsive forms [32].
As renin activity in patients with PA is constantly 
suppressed, aldosterone secretion is depends on ACTH 
stimulation to a greater degree than under physiological 
conditions. It also shows a diurnal rhythm with peak 
values between 8 and 9 o’clock in the morning [33]. 
Because of that morning measurements of ALDO for 
the purpose of determining PRA, in contrast to mea- 
surements performed at other times of the day, are 
considered more sensitive in the screening for PA [34].
Due to the fact that dietary salt restriction may lead to 
increased PRA values and the consequent reduction in 
ARR, salt restriction is not recommended in practice [29, 35].
The impact of gender, menstrual cycle, age and 
renal function on ARR
A relationship between the phase of the menstrual 
cycle and PRA and ALDO is observed in women [36, 
37]. Falsely elevated ARR values are more common 
in women. In about 30% of women on the 7th day of 
the cycle and in as many as 70% of women on the 21st 
day of the cycle ALDO values exceed 15 ng/dL, which 
is considered significant for PA [37]. The higher ARR 
values in pregnancy and in the luteal phase compared 
to the follicular phase are associated with the effects of 
progesterone, although the underlying mechanism is 
unclear [36, 38]. The recommendations of the Endocrine 
Society do not contain suggestions regarding selection 
of the phase of the menstrual cycle in which ARR should 
be performed, although some authors indicate that the 
best time point for screening for PA is the beginning of 
the cycle, when estrogen and progesterone levels are 
the lowest [38].
Figure 3. The impact of upright posture on PRA and ALDO under 
physiological conditions (the authors’ own studies)
Rycina 3. Wpływ pionizacji na aktywność reninową osocza 
(PRA) i stężenie aldosteronu w surowicy (ALDO) w warunkach 
fizjologicznych (baza — pozycja leżąca) — badania własne
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In patients with chronic kidney disease, especially in 
patients with impaired filtration, false positive ARR results 
are more common due to the direct and indirect (sodium 
and water retention) decrease in renin secretion and the 
possible increase in ALDO as a result of hyperkalaemia 
resulting from renal dysfunction [39]. Similarly, in the 
elderly, renin activity decreases as renal failure progresses, 
which predisposes to false positive ARR results [40].
Significance of potassaemia and its correction  
in the screening for PA
Although it is not a prerequisite for the diagnosis of PA, 
hypokalaemia warrants further evaluation in terms of 
this diagnosis, particularly in hypertensive patients. On 
the other hand, decreased serum potassium levels be-
fore screening must be corrected, as potassium excess 
stimulates aldosterone secretion and hypokalaemia 
decreases ALDO, increasing the likelihood of obtaining 
false negative ARR results [29, 35].
Impact of drugs on ARR
Drugs that may cause false positive ARR results
The possible impact of drugs on ARR is summarised in 
Table II. Because sympathetic stimulation — through 
stimulation of b2-adrenergic receptors and inhibition 
of a2-adrenergic receptors — increases renin activity, 
inhibition of these receptors by b-blockers and stimu-
lation by a-agonists, respectively, increases PRA. This 
may lead to falsely elevated ARR, as these drugs have 
potentially smaller effect on ALDO, which is indepen-
dently regulated by potassaemia and ACTH [35, 41]. 
However, Young believes that b-blockers do not exert 
a significant effect on ARR due to the simultaneous 
decrease in ALDO, parallel to the suppression of PRA 
[42]. Mulatero et al. have demonstrated no effect of 
a-blockers on ARR [43].
NSAIDs may decrease PRA by inhibiting pros-
taglandin synthesis and, as a consequence, increase 
ARR. NSAIDs also contribute to sodium and water 
retention, which may further inhibit PRA, and they 
also predispose to potassium retention, which increases 
ALDO [44].
Drugs that may cause false negative ARR results
Drugs that may increase PRA include diuretics, 
which stimulate renin activity by increasing sodium 
and water excretion [30]. Dihydropyridine calcium 
antagonists stimulate renin secretion, both directly 
(by affecting calcium-dependent regulating mecha-
nisms) and indirectly (by sympathetic stimulation 
and natriuretic effect caused by hypotension), and 
decrease ARR by 17% (with the exception of vera-
pamil, which exerts no effect) [43]. Angiotensin con-
verting enzyme inhibitors (ACEIs) and AT2-receptor 
blockers (ARBs) both inhibit the RASS and decrease 
ALDO and, as a consequence, ARR, by 30% and 
43%, respectively [43, 45]. Estrogen-containing oral 
contraceptives may slightly increase ARR by stimu-
lating angiotensinogen synthesis in the liver and the 
subsequent increase in ALDO [46]. Progesterone and 
progestins, most likely through the mineralocorticoid 
receptor, cause natriuresis, which stimulates renin 
secretion by the juxtaglomerular apparatus [47].
Table II. The impact of physiological and pharmacological factors on PRA and ALDO
Tabela II. Wpływ czynników fizjologicznych i farmakologicznych na PRA i ALDO
Type of stimulus PRA ALDO ARR
Physiological factors Upright position ↑↑ ↑↑↑ ↑↑↑
Time of day (morning effect of ACTH) (↑) ↑ ↑
Dietary sodium content (salt restriction) ↑↑ ↑ ↓
Menstrual cycle (luteal phase) – ↑ ↑
Age-related (> 65 years) decline  
of renal function 
↓ (↑) ↑↑
Hypokalaemia (↓) ↓↓ ↓↓
Pharmacological factors b-blockers, a2-agonists ↓ ↓/– –/↑
NSAIDs ↓ ↑ ↑
Diuretics ↑↑ ↑ ↓
Dihydropyridine calcium antagonists ↑↑ ↑ ↓
ACEIs and AT2-receptor blockers – ↓ ↓
Progestins ↑↑ ↑ ↓
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Practical comments on the measurement of ALDO 
and PRA for the purpose of determination of ARR
Blood should be sampled without the tourniquet 
(in order to avoid haemolysis) in the morning after 
5–15 minutes of sitting and two hours of keeping the 
chest in the upright position (walking, standing or 
sitting) [23]. The impact of upright posture on ARR is 
illustrated in Figure 4.
Not all the patients can be switched to antihyper-
tensives that do not affect PRA and ALDO (verapamil, 
a1-blockers, hydralazine) and in some cases discontinu-
ation of all the drugs that may affect ARR would simply 
be dangerous [48]. This does not, however, prevent the 
patient from being evaluated for PA, and taking into 
account the possible effect on the RAAS during interpre-
tation of the screening test results may be an important 
factor in deciding whether to continue or discontinue 
evaluation for PA. Increased ARR values in patients 
managed with drugs that may decrease ARR values 
(drugs that predispose to false negative ARR results), 
such as diuretics, ACEIs, ARBs and dihydropyridine cal-
cium antagonists, increase the likelihood of PA. Normal 
ARR in patients managed with drugs which that may 
cause false positive results, such as b-blockers, suggest 
ruling out the possibility of PA.
Practical comments on the interpretation of ARR
Another fact that should be taken into consideration 
is that PRA is very often decreased (in as many as 
every fourth patient with essential HT) and in 15% of 
the patients it is elevated (it is normal in 60% of the 
cases), which may significantly affect the value of ARR 
[49, 50]. It should also be borne in mind while analys-
ing ARR that the ALDO/PRA ratio may be increased 
not only in PA but also in secondary aldosteronism 
(commonly) and hypercortisolaemia (less commonly) 
(Figure 5).
Secondary aldosteronism refers to conditions in 
which excessive secretion of aldosterone results from 
increased PRA. The causes of secondary aldosteronism 
are summarised in Table III. Stimulation of the RAAS is 
most commonly caused by the reduction of “effective” 
circulating blood volume as a result of fluid escape 
outside the vascular bed. This is observed in patients 
with heart failure, liver cirrhosis and proteinuria. An 
absolute decrease in circulating blood volume is most 
commonly caused by the use of diuretics. Renal artery 
stenosis is caused by atherosclerosis in about 90% of 
the patients (more commonly in patients over the age 
of 50 years) or by fibromuscular dysplasia (in younger 
patients, more commonly in women) and leads to HT 
(renovascular HT). Reninoma, which is rare, is a cause 
of refractory HT with hypokalaemia, and this diagnosis 
is established in patients with secondary aldosteronism 
and unilateral overproduction of renin after renal artery 
stenosis has been ruled out [51].
What cutoff value of ARR rules out PA?
The variety of PRA and ALDO assays, their low repeat-
ability and the plethora of factors affecting the RAAS 
results in the considerable variation in cutoff values 
adopted by individual laboratories. Depending on the 
laboratory, the ARR cutoff values range from 7.2 to 100 
(ALDO expressed in ng/dL and PRA in ng/mL/h) [15, 
52–57]. Another difficulty for the clinician is the use of 
different units for the measurement of ALDO (ng/dL, 
pg/mL, pmol/L), where 1 ng/dL = 10 pg/mL = 27.7 
pmol/L.
Figure 5. Preliminary assessment of serum aldosterone (ALDO) 
and plasma renin activity (PRA) determinations
Rycina 5. Wstępna ocena wyników oznaczeń aldosteronemii 
(ALDO) i aktywności reninowej osocza (PRA)
Figure 4. The impact of upright posture on ARR under 
physiological conditions (the authors’ own studies); ALDO in 
ng/dL; PRA in ng/mL/h
Rycina 4. Wpływ pionizacji na wskaźnik ALDO/PRA (ARR, 
aldosterone–renin ratio) w warunkach fizjologicznych (baza 
— pozycja leżąca) — badania własne
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Mathematically, ARR values are determined by 
PRA to a greater degree than ALDO does, as the 
values of PRA may range from a hundredth to more 
than ten (four orders of magnitude) and those of 
ALDO from more than ten to several hundred (two 
orders of magnitude) [58]. In light of the above Young 
proposed to use ALDO values of > 15 ng/dL as the 
second essential criterion for a preliminary diagnosis 
of PA, in addition to ARR values of > 20 [56]. These 
criteria were met by 90% of Mayo Clinic patients in 
whom surgery confirmed the presence of adenoma 
[59]. According to other authors, this approach may 
result in missing the cases of PA also caused by APA 
[60]. A comparative analysis carried out by Schirpen-
bach et al. showed significant discrepancies between 
determinations of ALDO using 4 different assays 
[61]. Due to the more marked effect of PRA on ARR, 
particularly in view of the fact that the interpretation 
of ALDO determinations can be controversial, some 
authors attach more significance to the measurement 
of PRA as a stand-alone screening test [62].
In our studies, in the group of patients evaluated 
for PA, as many as 47% of the patients had ARR values 
exceeding 30 (the most commonly adopted cutoff value) 
and ARR values exceeding 50 were noted in as many as 
28%, which points to the low usefulness of this marker 
in the selection of patients requiring further investiga-
tion [63]. These data are illustrated in Figure 6.
The role of tests for confirming autonomous 
aldosterone secretion
The aim of the tests confirming PA is to demonstrate 
the lack of suppression of renin activity and, secondar-
ily, of aldosterone by stimuli that suppress the RAAS 
under physiological conditions. In practice, intravenous 
saline or the intravenous synthetic mineralocorticoid 
fludrocortisone are used. The lack of suppression of 
aldosterone secretion while using these agents confirms 
the autonomous nature of aldosterone secretion. The 
Table III. The causes of secondary aldosteronism (↑ALDO and ↑PRA and frequently ↑ARR) (the relatively common causes 
are in bold)
Tabela III. Przyczyny wtórnego aldosteronizmu (↑ALDO z ↑PRA i często ↑ARR) (względnie częste wyróżniono pogrubieniem)
With reduced “effective” blood volume Congestive heart failure
Liver cirrhosis
Nephrotic syndrome
With reduced circulating blood volume Diuretic treatment
Bartter syndrome
Gitelman syndrome
Pseudohypoaldosteronism type 1
With hypertension Malignant hypertension
Renal artery stenosis
Coarctation of the aorta
Reninom a
Figure 6. Percentages of patients with individual indications for 
evaluation for primary aldosteronism (PA) (n = 81) in whom the 
aldosterone-to-renin ratio (ARR) (serum aldosterone [ng/dL]/ 
/plasma renin activity [ng/mL/h]) exceeded specific cutoff values. 
ARR exceeding 30 was observed in 47% of the patients (source 
[63]); HT — arterial hypertension
Rycina 6. Odsetek pacjentów z poszczególnymi wskazaniami do 
diagnostyki w kierunku pierwotnego aldosteronizmu (PA) (n = 81), 
u których wskaźnik ARR (aldosteronemia [ng/dL]/aktywność 
reninowa osocza [ng/mL/h]) przekracza kolejne poziomy odcięcia; 
ARR przekraczające 30 stwierdzono u 47% badanych (źródło [63]); 
HT — nadciśnienie tętnicze
(%
)
> 20
60
50
40
30
20
10
0
> 30 > 40 > 50 > 180
Refractory HT
HT with hypokalaemia
HT with the onset below 40 years of age
Adrenal incidentaloma
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captopril test is less useful clinically than these two 
tests [64].
The results of our study in 198 patients evaluated 
for PA show that the routine use of the salt loading 
test to demonstrate autonomy of aldosterone secre-
tion effectively narrows down the group of patients 
for further investigation while only slightly increasing 
the cost of diagnostic evaluation. The lack of suppres-
sion of aldosterone secretion with salt below 6.5 ng/dL 
under conditions of suppressed PRA allows to confirm 
the diagnosis of PA with a high sensitivity and a high 
specificity (Figure 7) [65].
Intravenous saline infusion test
The commonly used protocol for this test involves 
intravenous administration of two litres of 0.9% 
NaCl over 4 hours, followed by measurement of 
ALDO. The patient should remain recumbent. The 
cutoff values for the confirmation of PA vary from 
laboratory to laboratory and range from 5 to 10 ng/ 
/dL (140–280 pmol/L) [65, 66]. This test is prob- 
ably the most commonly used test for autonomous 
aldosterone secretion due the ease of performance 
and the short duration. Simultaneous determination 
of PRA is aimed to confirm that the potential lack 
of suppression of aldosterone secretion is observed 
under conditions of suppressed PRA (in contrast to 
secondary aldosteronism) and is not secondary to 
factors that stimulate renin activity (mainly antihy-
pertensive drugs). The effects of 2 litres of 0.9% NaCl 
on PRA and ALDO under physiological conditions 
are illustrated in Figure 8.
In each case the individual risk of HT and hear 
failure worsening should be taken into account [67].
Oral salt loading test
In order to confirm PA, some authors, including Young 
et al., measure aldosterone levels in the urine follow-
ing oral administration of salt [56]. In this protocol, 
after achieving normal blood pressure and normal 
serum potassium levels, the patient is asked to follow 
a high-sodium diet for 3 days. The diet should contain 
5 g of sodium (12.8 g of sodium chloride) [31]. The 
sodium supply should be intensive enough to achieve 
urinary sodium excretion exceeding 200 mEq/day. As 
a high-sodium diet stimulates kaliuresis and, as a con-
sequence, causes hypokalaemia, serum potassium levels 
should be monitored every day and corrected, if neces-
sary. The lack of reduction in the 24-hour aldosterone 
excretion confirms PA. In each case the individual risk 
of HT and hear failure worsening should be taken into 
account [67].
Fludrocortisone suppression test
The test involves administration of 0.1 mg of fludro-
cortisone acetate every 6 hours and 2 g of sodium 
chloride (with main meals) 3 times daily — for 
4 days. Serum aldosterone levels exceeding 5 ng/dL on 
day four confirms the diagnosis of PA. In some centres 
the fludrocortisone suppression test is considered the 
most reliable [30, 35], while in other centres, including 
the Mayo Clinic, it is not used, as it is considered to 
be unsafe due to the variability of the QT interval and 
worsening of left ventricular function observed dur-
ing the test [67]. Mulatero et al. showed a comparable 
diagnostic value of this test and of the intravenous 
salt loading test [43].
Figure 7. The sensitivity and specificity of plasma aldosterone 
determination in the salt loading test (source [65]); ALDO — 
plasma aldosterone levels
Rycina 7. Czułość i swoistość oznaczeń aldosteronemii w teście 
z NaCl (źródło [65]); ALDO — stężenie aldosteronu w osoczu
Figure 8. The effects of 2 litres of 0.9% NaCl on PRA and ALDO 
under physiological conditions
Rycina 8. Wpływ 2 litrów 0,9-procentowego roztworu chlorku 
sodu (NaCl) na aktywność reninową osocza (PRA) i stężenie 
aldosteronu w osoczu (ALDO) w warunkach fizjologicznych
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Aetiological diagnosis of primary aldosteronism
Adenoma and bilateral adrenal hyperplasia are two 
most common causes of PA (both characterised by 
a similar prevalence). Unilateral adenoma is the cause 
of aldosterone excess in 30–60% of the patients with 
PA. PA is much less commonly (3–5% of the cases) 
caused by unilateral micro- or macronodular adrenal 
hyperplasia. Familial forms of PA — familial hyper- 
aldosteronism (FH) types I and II — are even rarer [68]. 
FH type I, or glucocorticoid-remediable aldosteronism 
(GRA), is an autosomal dominant condition. This form 
of PA is characterised by manifestations of aldoster-
one excess of varying severity and increased levels of 
18-hydroxycortisol and 18-oxocortisol, which result 
from expression of a hybrid gene, and by responsive-
ness to corticosteroid treatment [69]. Genetic testing 
for GRA should be performed in relatives of patients 
with GRA, relatives of patients with a history of stroke 
at a young age, and patients with diagnosed with PA 
before the age of 20 years [70]. FH type I in the Polish 
population is most probably sporadic, as evidenced by 
the lack of the hybrid aldosterone gene typical of GRA 
in 129 patients with PA [71]. FH type II predisposes to 
the familial occurrence of APA, BAH or both [72]. FH 
type II may be a monogenic or an autosomal dominant 
condition. FH type II should be suspected in cases of 
familial occurrence of PA after GRA has been ruled out. 
The incidence of FH type II is estimated to be higher 
than that of GRA [72].
The histopathological presentations of PA vary con-
siderably (Figure 9) and contain in their spectrum the 
typical APA, APA co-existing with nodular hyperplasia 
(in various proportions) and the typical BAH, which 
may be micro- or macronodular [73]. Mixed forms, in 
which BAH overlaps with APA, are also common. The 
differentiation between the individual forms of PA is 
essential for the selection of conservative or surgical 
therapy in cases of aldosterone excess caused by BAH 
or APA, respectively. It is estimated that APA is the cause 
of HT in 2.5% of the patients. The percentage of candi-
dates for adrenalectomy for PA is the same. In practice, 
the establishment of the cause of hyperaldosteronism is 
often impossible, as the demonstration of adenoma or 
hyperplasia is not decisive in establishing the aetiology 
of PA, particularly since non-functioning adrenal adeno-
mas occur in 5–10% of the general population and their 
prevalence increases with age [74, 75]. Measurements 
of aldosterone levels in blood sampled during adrenal 
vein catheterisation (AVC) have shown that the cause 
of PA may be localised contralateral to the identified 
adenoma, may be caused by bilateral adenomas or by 
unilateral overproduction of aldosterone despite signs 
of hyperplasia in both adrenal glands [30, 76]. PA is 
only exceptionally caused by adrenal carcinoma, which 
is usually characterised by a diameter exceeding 4 cm 
an a heterogenous structure [74].
Detection of a solitary homogenous hypodense 
lesion of an adenomatous nature (density < 10 Houns-
field units [HU]) in the presence of an intact contralat-
eral adrenal gland in a young (aged < 40 years) patient 
justifies adrenalectomy [23]. Patients with PA caused by 
APA are usually characterised by a higher grade of HT, 
hypokalaemia and higher ALDO values. Aldosterono-
mas can, however, be microadenomas (< 1 cm) and for 
this reason they may not be detected by CT and may 
erroneously suggest adrenocortical hypertrophy. In 
one of the studies CT revealed unilateral lesions only 
in 55 out of 111 patients with surgically confirmed APA 
and CT scans revealed only 25% of microadenomas 
[77]. In another study of 203 patients, APA was cor-
rectly differentiated from BAH in a mere 53% of the 
patients: 1/5 of the patients would have been incor-
rectly considered ineligible for adrenalectomy and 
1/4 of the patients would have undergone unnecessary 
surgery [78]. For this reason AVC is necessary in most 
patients considered for adrenalectomy.
AVC is an invasive procedure and not an easy one 
to perform, mainly because of the small diameter of the 
right adrenal vein [31, 78, 79]. Hence the radiologist’s 
experience and manual skills are of key importance. In 
order to minimise the impact of stress on aldosterone 
secretion the patients are often started on cosyntro-
pin infusion at the dose of 50 mg/h 30 minutes prior 
to catheterisation with the infusion being continued 
until completion of the procedure. An ALDO grad- 
ient of more than 4:1 confirms a unilateral cause of PA 
(sensitivity 95%, specificity 100%), while a gradient of 
less than 3:1 indicates a bilateral cause of aldosterone 
excess [78]. In centres with expertise the incidence of 
complications is about 2.5%. The complications include: 
haematoma, adrenal haemorrhage and adrenal vein 
dissection [78, 79].
Figure 9. The histopathology of primary aldosteronism
Rycina 9. Obraz histopatologiczny pierwotnego aldosteronizmu
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Treatment
The aim of the treatment of PA is to normalise blood 
pressure and serum potassium levels and to prevent 
cardiovascular damage.
Unilateral adrenalectomy is usually reserved for 
cases of PA caused by excessive secretion of aldoster-
one by one adrenal gland (APA or, rarely, hyperpla-
sia). Laparoscopic adrenalectomy is recommended, 
as it makes it possible to shorten hospitalisation and 
reduce the number of complications [8, 9]. In the 
preparation of patients with PA for adrenalectomy 
pharmacotherapy with aldosterone antagonists and 
thiazide diuretics are used to normalise blood pres-
sure and potassium levels. In patients with BAH, 
even bilateral adrenalectomy rarely results in blood 
pressure normalisation, which is why the treatment 
of choice involves the use of drugs which counter-
act aldosterone effects, especially since the removal 
of both adrenals is associated with the necessity of 
lifetime replacement treatment with adrenal cortex 
hormones [31]. Unilateral adrenalectomy in some 
selected patients with BAH may significantly re-
duce the severity of HT by reducing the mass of 
aldosterone-producing tissue [80]. Confirmation of 
lateralisation by means of AVC is usually a decisive 
factor in qualifying the patient for surgery, which 
leads to normalisation of potassaemia in nearly all 
of the patients and corrects HT in 30–60% or at least 
improves it in the remaining patients, making it 
possible to reduce the intensity of antihypertensive 
treatment [10, 68, 81, 82]. Therefore, in about 50% 
of the patients undergoing adrenalectomy, it is not 
possible to discontinue antihypertensive treatment 
[83, 84]. If permanent normalisation of blood pres-
sure is achieved (without the use of antihypertensive 
medication) following laparoscopic adrenalectomy, it 
is the least expensive method of treatment in the long 
term [85]. Surgery fails to normalise blood pressure 
in older patients, in patients with a longer-standing 
HT, with a greater likelihood of the co-existence of 
essential HT (familial occurrence) and in patients 
with renal impairment [81, 82]. Patients with high 
ALDO and extremely decreased PRA have a better 
chance of achieving a complete resolution of HT after 
adrenalectomy causing PA [10].
The reason for the persistence of HT despite the 
correction of elevated serum aldosterone by adrenal 
surgery in the patient with PA is the usually co-existent 
primary HT and/or glomerulosclerosis resulting form 
long-standing uncontrolled HT in the arterial system 
[83, 84]. In some patients, the failure to fully correct 
HT following adrenalectomy may be associated with 
an incorrect classification of the cause of PA on the basis 
of imaging studies (without AVC) as unilateral, while 
in reality the PA is caused by BAH, which should be 
treated pharmacologically [10].
Young et al. proposed the aldosterone resolution 
score (ARS) to help clinicians to more correctly select 
patients most likely to achieve normal blood pressure 
following adrenalectomy [85]. Based on a study of 100 
patients with PA at Mayo Clinic four clinical features 
characterised by the highest predictive value as regards 
the chances of complete resolution of HT after resection 
of the affected adrenal gland. Each of the four features 
of the ARS score was assigned 1 or 2 points to differ-
entiate the predictive value (Table IV). According to 
the authors it may be predicted normalisation of blood 
pressure following adrenalectomy will be achieved by 
every only fourth patient with an ARS of 0–1, every 
second patient with an ARS of 2–3 and three fourths of 
patients with an ARS of 4–5. ARS requires verification 
in studies conducted by other centres.
For those patients with PA who are not eligible for 
adrenal surgery due to BAH, low ARS or the refusal 
of consent treatment with mineralocorticoid receptor 
agonists is a viable alternative [87]. Treatment used for 
more than 5 years also in patients with APA effectively 
maintains normal blood pressure and normal potassae-
mia. Important elements of the conservative treatment 
of HT, including HT caused by PA, is low-salt diet (< 
100 mEq of sodium daily), maintaining normal body 
weight, not smoking, not abusing alcohol and regular 
aerobic exercises [68].
No randomised controlled studies have so far been 
conducted to assess the efficacy of various pharma-
ceuticals in patients with PA, although spironolactone 
is an effective, tried and tested first-line drug in these 
patients. The drug should be given at doses that make 
it possible to achieve normal potassium levels without 
the need for supplementation. Spironolactone is given 
Table IV. Aldosterone Resolution Score (ARS) (source [86])
Tabela IV. Skala oceny szansy na wyleczenie aldosteronizmu 
(źródło [86])
Clinical feature Points
≤ 2 antihypertensive drugs 2
BMI ≤ 25 kg/m2 1
Hypertension of ≤ 6 years’ duration 1
Female sex 1
ARS % patients cured
0–1 27 (approx. 1/4)
2–3 46 (approx. 1/2)
4–5 75 (3/4)
BMI — body mass index
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with food, which increases its absorption, starting from 
25 mg daily and increasing the dose every 2 weeks [23].
The mineralocorticoid receptor antagonist class 
includes spironolactone (a non-selective antagonist) 
and eplerenone (a selective antagonist). Doses should 
be increased until normalisation of potassaemia is 
achieved. Normalisation of blood pressure is achieved 
later, after 4–8 weeks of pharmacotherapy. After normal 
blood pressure values have been achieved the doses of 
antihypertensive medication can be reduced in some 
patients. After initiation of treatment serum potassium 
and creatinine levels should be monitored, initially 
every month, particularly in patients with renal failure 
and diabetes mellitus. NSAIDs should not be combined 
with spironolactone, as they interfere with tubular ex-
cretion of its active metabolites, decreasing its efficacy. 
Spironolactone, on the other hand, prolongs the half-life 
of digoxin, potentiating its effects. As it is not a selective 
antagonist of the aldosterone receptor, spironolactone 
may also bind with the testosterone receptor, result-
ing in painful gynaecomastia, libido abnormalities in 
men and menstrual disorders in women, due to the 
stimulation of progesterone receptors. The frequency 
of gynaecomastia during spironolactone treatment de-
pends on the dose: gynaecomastia affects 7% of patients 
receiving the dose of 50 mg/day and 52% of patients 
receiving the dose of 150 mg/day [87]. Eplerenone is 
a selective inhibitor of aldosterone receptors showing 
a 1000-fold lower affinity for the testosterone recep-
tor and a 100-fold lower affinity for the progesterone 
receptor compared to spironolactone. In addition, the 
half-life of eplerenone is shorter, which is why it has 
to be given twice daily. It is recommended that the 
conservative treatment of PA should be initiated with 
spironolactone and if adverse effects develop, espe-
cially gynaecomastia, the patient should be switched to 
eplerenone. Despite head-to-head comparative studies 
of the potency of spironolactone and eplerenone the 
former is considered to be more effective. Eplerenone 
is more expensive. However, being more selective, 
eplerenone is not associated with such a high frequency 
of gynaecomastia as spironolactone [23].
Patients with BAH usually require long antihyper-
tensive treatment before good blood pressure control 
is achieved. Taking into account that hypovolaemia is 
the most common reason for resistance to treatment, 
hydrochlorothiazide is often added at the daily dose 
of 12.5–50 mg. Potassium-sparing diuretics, amiloride 
and triamterene (sodium channel inhibitors), are not 
recommended as the principal drugs in PA, as they do 
not counteract the undesirable effect of aldosterone 
excess on the cardiovascular system, although they 
can supplement the effects of aldosterone antagonists 
in normalising blood pressure and potassaemia. The 
second group of antihypertensive drugs that can be 
used are ACEIs, which reduce the levels of serum AII, 
a stimulator of aldosterone secretion, especially in pa-
tients with BAH [87].
Before the initiation of treatment of GRA with a cor-
ticosteroid the diagnosis should be confirmed by genetic 
testing and the doses of the steroid should be optimised, 
while avoiding the occurrence of hypercortisolaemia.
Conclusions
Studies conducted in the past few years demonstrate 
that PA is a common, potentially curable cause of hy-
pertension and an important cardiovascular risk factor. 
Taking this into consideration recommendations have 
been developed under the aegis of the of Endocrine 
Society for the diagnosis and treatment of PA, as a valu-
able guide for clinicians. While the diagnosis of PA is 
key, the evaluation of PA is associated with consider-
able errors, especially in terms of false positive results, 
due to the imperfection of laboratory assays and the 
influence of numerous factors. Hence the authors of 
the document recommend that each case should be 
considered individually. The demonstration of the au-
Figure 10. A diagnostic and therapeutic algorithm in primary 
aldosteronism; PRA — plasma renin activity; ALDO — serum 
aldosterone levels; CT — computed tomography; AVC — adrenal 
vein catheterization
Rycina 10. Algorytm postępowania diagnostyczno-leczniczego 
w pierwotnym aldosteronizmie (PA); PRA — aktywność 
reninowa osocza; ALDO — stężenie aldosteronu w surowicy; 
CT — tomografia komputerowa; AVC — cewnikownie żył 
nadnerczowych
Hypertension in a patient at risk of PA
Mineralocorticoid
receptor antagonists
Screening
Ø ≠ ≠PRA and/or ALDO and/or ALDO/PRA
Autonomous secretion of ALDO?
Confirmatory tests
Lack of ALDO suppression following administration
of salt (and/or fludrocortisone)
Confirmed PA
Aetiological evaluation
Surgery not considered
CT
Surgery?
Lateralisation?
Adrenalectomy
AVC
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tonomy of aldosterone secretion in a confirmatory test 
effectively selects patients for the much more expen-
sive causative evaluation of PA without significantly 
increasing the costs of evaluation. From the therapeutic 
point of view, the causes of PA may be divided into 
unilateral (APA, unilateral adrenal hyperplasia and 
adrenal carcinoma), in which laparoscopic adrenalec-
tomy is recommended, and bilateral (BAH and, rarely, 
GRA). As on the one hand aldosteronomas are often 
small tumours but on the other hand a considerable 
percentage of the population has non-functioning 
adenomas, the CT presentation is not conclusive as 
to the location of the source of excess aldosterone 
(with the exception of young patients). If the patient 
is a potential candidate for surgery, he should undergo 
AVC, which — in most cases — is conclusive as to 
whether the cause of PA is unilateral (and the patient 
is eligible for adrenalectomy) or bilateral (in which 
case the treatment should involve administration of 
aldosterone antagonists). Conservative treatment 
should also be offered to patients with PA who refuse 
to undergo surgery or are not appropriate candidates 
for it due to contraindications or little changes of ben-
efitting from this modality. The aim of the treatment 
of PA, irrespective of the cause, is to achieve normal 
potassaemia, normal blood pressure and to minimise 
the adverse consequences of aldosterone effects on the 
cardiovascular system.
A diagnostic and therapeutic algorithm in PA is 
presented in Figure 10.
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